Integrated AI-driven System for Early Detection of Cervical and Breast Cancer Using Multi-Modal Imaging, Liquid Biopsy, and Epigenetic Biomarkers.
OwnerFurong Beiinventor
Life of this patent
Estimating the term…
Loading patent…
OwnerFurong Beiinventor
Estimating the term…
A quantum-dot-enhanced CRISPR-Cas13a microfluidic molecular triage and clinical routing system for rapid high-risk human papillomavirus genotyping in cervical and breast cancer care pathways includes a disposable microfluidic cartridge and a reader for rapid genotyping of high-risk human papillomavirus from cervical samples. The cartridge includes a sample inlet, lysis zone, CRISPR reaction zone, optical detection zone, and waste reservoir. At least one reaction microchannel has a width of about 100 micrometers and a depth of about 50 micrometers. A CRISPR-Cas13a assay is incubated at about 37 degrees Celsius for about 15 minutes. Fluorescence from a quantum-dot reporter having a peak emission at about 605 nanometers is detected to generate a same-visit triage output indicating HPV16/18 positive, other high-risk HPV positive, negative, invalid, or repeat-test recommended. Optional communications features support secure transmission of results or run metadata to patient, provider, emergency, or reimbursement interfaces.
A quantum-dot-enhanced CRISPR-Cas13a microfluidic molecular triage system for rapid genotyping of high-risk human papillomavirus (HPV) from a cervical sample, comprising:
A method for rapid high-risk HPV genotyping and same-visit triage using a cervical sample, comprising:
A kit for quantum-dot-enhanced CRISPR-Cas13a microfluidic molecular triage of a cervical sample, comprising:
Dependencies are inferred from the claim text.